Alumis Inc. (ALMS) is having a rough Tuesday. The biotech's stock is down more than half after the company released topline data from its Phase 2b LUMUS trial, which tested envudeucitinib in patients with moderate-to-severe systemic lupus erythematosus. The study didn't meet its primary or secondary endpoints across the whole trial population, and investors are reacting accordingly.
But here's the twist: buried in the data is a signal that could actually be quite promising. A prespecified subgroup analysis revealed robust clinical responses among patients with a high interferon gene signature. In that target population, envudeucitinib hit the primary endpoint, which was measured using the British Isles Lupus Assessment Group–based Composite Lupus Assessment. It also achieved key secondary endpoints, including the SLE Responder Index 4, Cutaneous Lupus Erythematosus Disease Area and Severity Index 50, and Lupus Low Disease Activity State.
So why did the overall trial fail? It comes down to patient composition. Investigators classified participants using a commercially available interferon gene signature assay. Patients with high signatures make up the majority of moderate-to-severe lupus cases, typically respond better to targeted interferon therapies, and tend to have lower placebo response rates. But in the LUMUS trial, high-signature patients were unexpectedly under-represented, which dragged down the response rates across the entire study population.
That's a classic case of the right drug in the wrong patient mix. The company argues that these insights establish a clear path forward for regulatory discussions on Phase 3 development. And the data on the drug itself is encouraging: pharmacodynamic results confirmed strong, dose-dependent target engagement, with maximal suppression at the highest dose of 40mg twice-daily. Envudeucitinib was also well tolerated, with a favorable safety profile and no new safety signals identified.
At the time of publication on Tuesday, Alumis shares were down 54.84% at $9.850, according to market data. That's a brutal drop, but for investors willing to look past the headline numbers, the subgroup data might be the real story. The question now is whether regulators will agree that the path forward is as clear as Alumis suggests.
